Prognostic value of IMP3 expression as a determinant of chemosensitivity in triple-negative breast cancer
Authors:
- 1 September 2017
- journal article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 213 (9) , 1160-1165
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Utility of neoadjuvant chemotherapy in the treatment of operable breast cancerAnz Journal of Surgery, 2015
- Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical TrialsInternational Journal of Breast Cancer, 2012
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologistsLaboratory Investigation, 2011
- Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancerLaboratory Investigation, 2010
- Diffuse Expression of RNA-Binding Protein IMP3 Predicts High-Stage Lymph Node Metastasis and Poor Prognosis in Colorectal AdenocarcinomaAnnals of Surgical Oncology, 2009
- The Oncofetal Protein IMP3American Journal of Surgical Pathology, 2008
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- KOC (K Homology Domain Containing Protein Overexpressed in Cancer)American Journal of Surgical Pathology, 2005
- The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesisGene, 2002
- A family of IGF-II mRNA binding proteins (IMP) involved in RNA traffickingScandinavian Journal of Clinical and Laboratory Investigation, 2001